Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.
暂无分享,去创建一个
E. Melamed | O. Bernard | S. Gorodin | D. Offen | P. Beart | N. Cheung | A. Hochman | C. Pascoe | R. Bernard
[1] Xiaodong Wang,et al. Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.
[2] Y. Agid,et al. Expression of Bcl‐2 in Adult Human Brain Regions with Special Reference to Neurodegenerative Disorders , 1997, Journal of neurochemistry.
[3] A. Barzilai,et al. Dopamine–melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease , 1997, Neurochemistry International.
[4] Guido Kroemer,et al. The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.
[5] M. Jacobson. Apoptosis: Bcl-2-related proteins get connected , 1997, Current Biology.
[6] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[7] P. Beart,et al. (S)-5-fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors. , 1996, European journal of pharmacology.
[8] G. Kroemer,et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease , 1996, The Journal of experimental medicine.
[9] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[10] Y. Mizuno,et al. bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.
[11] L. Ellerby,et al. Shift of the Cellular Oxidation‐Reduction Potential in Neural Cells Expressing Bcl‐2 , 1996, Journal of neurochemistry.
[12] I. Ziv,et al. Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.
[13] L. Maffei,et al. Protection of Retinal Ganglion Cells from Natural and Axotomy-Induced Cell Death in Neonatal Transgenic Mice Overexpressing bcl-2 , 1996, The Journal of Neuroscience.
[14] Y. Mizuno,et al. Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.
[15] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] A. Barzilai,et al. Dopamine-induced programmed cell death in mouse thymocytes. , 1995, Biochimica et biophysica acta.
[17] K. O’Malley,et al. Overexpression of Bcl-2 attenuates MPP+, but not 6-ODHA, induced cell death in a dopaminergic neuronal cell line , 1995, Neurobiology of Disease.
[18] N. Hattori,et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. , 1995, Biochimica et biophysica acta.
[19] S. Rees,et al. bcl-2 transgene expression can protect neurons against developmental and induced cell death. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] Jean-Claude Martinou,et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia , 1994, Neuron.
[21] M. Dubois‐Dauphin,et al. Neonatal motoneurons overexpressing the bcl-2 protooncogene in transgenic mice are protected from axotomy-induced cell death. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Barzilai,et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons — A possible novel pathogenetic mechanism in Parkinson's disease , 1994, Neuroscience Letters.
[23] Z. Oltvai,et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.
[24] A. Harris,et al. bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.
[25] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[26] J. Martinou,et al. Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. , 1992, Science.
[27] C. Mytilineou,et al. 1-methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture , 1985, Neuroscience Letters.
[28] H. Pakkenberg,et al. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, The New England journal of medicine.
[29] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[30] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[31] W B Jakoby,et al. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. , 1974, The Journal of biological chemistry.
[32] E. Zamrini,et al. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.
[33] O. Bernard,et al. NSE-bcl-2 transgenic mice, a model system for studying neuronal death and survival. , 1997, Developmental neuroscience.
[34] B. Mannervik,et al. [59] Glutathione reductase , 1985 .
[35] G H Sato,et al. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. , 1979, Proceedings of the National Academy of Sciences of the United States of America.